Details for Patent: 11,712,459
✉ Email this page to a colleague
Which drugs does patent 11,712,459 protect, and when does it expire?
Patent 11,712,459 protects REZZAYO and is included in one NDA.
This patent has twelve patent family members in seven countries.
Drugs Protected by US Patent 11,712,459
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mundipharma | REZZAYO | rezafungin acetate | POWDER;INTRAVENOUS | 217417-001 | Mar 22, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS WITH REZAFUNGIN BY INTRAVENOUS ADMINISTRATION | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,712,459
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 3017485 | ⤷ Sign Up | |||
| China | 109154603 | ⤷ Sign Up | |||
| European Patent Office | 3430400 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
